Abstract
St. John's wort is widely used as an herbal remedy for depression. Although its mechanism of action remains unknown, some evidence suggests that St. John's wort might act via brain serotonin (e.g., as a serotonin reuptake inhibitor). To determine whether St. John's wort affects the central serotonergic system, we monitored the discharge rate of serotonin-containing neurons in the dorsal raphe nucleus of awake cats following systemic administration of two clinical preparations of St. John's wort, Jarsin® 300 (15–600 mg/kg, p.o.) and Hyperforat® (0.5–4.0 ml, i.v.). Both preparations were found to have no effect on neuronal activity. This contrasts sharply with the action of fluoxetine and sertraline (2 mg/kg, p.o.), two selective serotonin reuptake inhibitors (SSRIs), which markedly depressed neuronal activity by increasing the synaptic availability of serotonin at inhibitory somatodendritic 5-HT1A autoreceptors. The failure of St. John's wort to depress neuronal activity cannot be attributed to an impairment of the 5-HT1A autoreceptor mechanism, since pretreatment with Jarsin® 300 (300 mg/kg, p.o.) did not alter the responsiveness of serotonergic neurons to the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (10 μg/kg, i.v.). Overall, these findings indicate that the mode of action of St. John's wort is different from that of conventional antidepressant drugs, which elevate brain serotonin and evoke negative feedback control of serotonergic neurons.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Adell A, Artigas F . (1991): Differential effects of clomipramine given locally or systemically on extracellular 5-HT in raphe nuclei and frontal cortex. An in vivo brain dialysis study. Naunyn Schmiedebergs Arch Pharmacol 343: 237–244
Aghajanian GK, VanderMaelen CP . (1986): Specific systems of the reticular core: serotonin. Handb Physiol 4: 237–256
Aghajanian GK, Wang RY . (1978): Physiology and pharmacology of central serotonergic neurons. In Lipton MA, Di Mascio A, Killam KF (eds), Psychopharmacology: A Generation of Progress. New York, Raven Press, pp 171–183
Artigas F . (1993): 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol Sci 14: 262
Artigas F, Romero L, de Montigny C, Blier P . (1996): Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378–383
Baldessarini R . (1996): Drugs and the treatment of psychiatric disorders. Depression and mania. In Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., New York, McGraw-Hill, pp 431–459
Béıuml;que JC, de Montigny C, Blier P, Debonnel G . (1999): Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affintity for reuptake sites. Synapse 32: 198–211
Bennett DA Jr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB . (1998): Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother 32: 1201–1208
Bhattacharya SK, Chakrabarti A, Chatterjee SS . (1998): Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry 31(Suppl 1): 22–29
Biber A, Fischer H, Römer A, Chatterjee SS . (1998): Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31(Suppl 1): 36–43
Bladt S, Wagner H . (1994): Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 7(Suppl 1): S57–S59
Blier P, de Montigny C . (1994): Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220–226
Blier P, de Montigny C, Chaput Y . (1990): A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 51(Suppl 4): 14–20
Bjorvatn B, Fornal CA, Martín FJ, Metzler CW, Jacobs BL . (2000): Venlafaxine and its interaction with WAY 100635: effects on serotonergic unit activity and behavior in cats. Eur J Pharmacol 404: 121–132
Brockmöller J, Reum T, Bauer S, Kerb R, Hübner W-D, Roots I . (1997): Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30(Suppl 2): 94–101
Bunk S . (1999): St. John's wort set for U.S. clinical trials. The Scientist 13: 10
Butterweck V, Wall A, Liefländer-Wulf U, Winterhoff H, Nahrstedt A . (1997): Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 30(Suppl 2): 117–124
Calapai G, Crupi A, Firenzuoli F, Costantino G, Inferrera G, Campo GM, Caputi AP . (1999): Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol 51: 723–728
Ceci A, Baschirotto A, Borsini F . (1994): The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 33: 709–713
Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE . (1998): Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63: 499–510
Constantine GH, Karchesy J . (1998): Variations in hypericin concentrations in Hypericum perforatum L. and commercial products. Pharm Biol 36: 365–367
Cott JM . (1997): In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30(Suppl 2): 108–112
Czachura JF, Rasmussen K . (2000): Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch Pharmacol 362: 266–275
Demisch L, Hölzl J, Gollnik B, Kaczmarczyk P . (1989): Identification of selective MAO-type-A inhibitors in Hypericum perforatum L. (Hyperforat®). Pharmacopsychiatry 22: 194
Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E . (2000): Effect of acute administration of Hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system. Pharmacopsychiatry 33: 14–18
Ernst E, Rand JI, Barnes J, Stevinson C . (1998): Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 54: 589–594
Fornal CA, Jacobs BL . (1988): Physiological and behavioral correlates of serotonergic single-unit activity. In Osborne NN, Hamon M (eds), Neuronal Serotonin. New York, John Wiley & Sons, pp 305–345
Fornal CA, Martín FJ, Metzler CW, Jacobs BL . (1999): Pindolol, a putative 5-hydroxytryptamine1A antagonist, does not reverse the inhibition of serotonergic neuronal activity induced by fluoxetine in awake cats: comparison to WAY-100635. J Pharmacol Exp Ther 291: 220–228
Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC, Jacobs BL . (1996): WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther 278: 752–762
Fox E, Murphy RF, McCully CL, Adamson PC . (2001): Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 47: 41–44
Gartside SE, Umbers V, Sharp T . (1997): Inhibition of 5-HT cell firing in the DRN by non-selective 5-HT reuptake inhibitors: studies on the role of 5-HT1A autoreceptors and noradrenergic mechanisms. Psychopharmacology 130: 261–268
Gaster B, Holroyd J . (2000): St John's wort for depression. A systematic review. Arch Intern Med 160: 152–156
Gobbi M, Valle FD, Ciapparelli C, Diomede L, Morazzoni P, Verotta L, Caccia S, Cervo L, Mennini T . (1999): Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 360: 262–269
Hajós M, Hajós-Korcsok E, Sharp T . (1999): Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 126: 1741–1750
Hervás I, Artigas F . (1998): Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptor. Eur J Pharmacol 358: 9–18
Hippius H . (1998): St John's wort (Hypericum perforatum) – a herbal antidepressant. Curr Med Res Opin 14: 171–184
Hyttel J . (1994): Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1): 19–26
Invernizzi R, Belli S, Samanin R . (1992): Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584: 322–324
Jacobs BL, Azmitia EC . (1992): Structure and function of the brain serotonin system. Physiol Rev 72: 165–229
Jacobs BL, Gannon PJ, Azmitia EC . (1984): Atlas of serotonergic cell bodies in the cat brainstem: an immunocytochemical analysis. Brain Res Bull 13: 1–31
Jensen AG, Hansen SH, Nielsen EØ . (2001): Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci 68: 1593–1605
Josey ES, Tackett RL . (1999): St. John's wort: a new alternative for depression? Int J Clin Pharmacol Ther 37: 111–119
Kim HL, Streltzer J, Goebert D . (1999): St. John's wort for depression. A meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187: 532–538
Koe BK, Weissman A, Welch WM, Browne RG . (1983): Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 226: 686–700
Kumar V, Singh PN, Jaiswal AK, Bhattacharya SK . (1999): Antidepressant activity of Indian Hypericum perforatum Linn in rodents. Indian J Exp Biol 37: 1171–1176
Kurth H, Spreemann R . (1998): Phytochemical characterization of various St. John's Wort extracts. Adv Ther 15: 117–128
Laakmann G, Schüle C, Baghai T, Kieser M . (1998): St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31(Suppl 1): 54–59
Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D . (1996): St John's wort for depression–an overview and meta-analysis of randomised clinical trials. Br Med J 313: 253–258
Liu FF, Ang CYW, Heinze TM, Rankin JD, Beger RD, Freeman JP, Lay JO Jr . (2000): Evaluation of major active components in St. John's Wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation. J Chromatogr A 888: 85–92
Maes M, Meltzer HY . (1995): The serotonin hypothesis of major depression. In FE Bloom, Kupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 933–944
Müller WE, Kasper S . (1997): Editorial. Pharmacopsychiatry 30(Suppl 2): 71
Müller WE, Rolli M, Schäfer C, Hafner U . (1997): Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 30(Suppl 2): 102–107
Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C . (1998): Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31(Suppl 1): 16–21
Nathan P . (1999): The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry 4: 333–338
Neary JT, Bu Y . (1999): Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 816: 358–363
Perovic S, Müller WEG . (1995): Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 45: 1145–1148
Romero L, Casanovas JM, Hervás I, Cortés R, Artigas F . (1997): Strategies to optimize the antidepressant action of selective serotonin reuptake inhibitors. In Skolnick P (ed), Antidepressants: New Pharmacological Strategies. Totowa, Humana Press, pp 1–33
Singer A, Wonnemann M, Müller WE . (1999): Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 290: 1363–1368
Snider RS, Niemer WT . (1970): A Stereotaxic Atlas of the Cat Brain. Chicago, The University of Chicago Press
Sprouse JS, Aghajanian GK . (1986): (-)- Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol 128: 295–298
Sprouse JS, Clarke T, Reynolds L, Heym J, Rollema H . (1996): Comparison of the effects of sertraline and its metabolite desmethysertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 14: 225–231
Stevinson C, Ernst E . (1999): Hypericum for depression. An update of the clinical evidence. Eur Neuropsychopharmacol 9: 501–505
Stock S, Hölzl J . (1991): Pharmacokinetic test of [14C]-labelled hypericin and pseudohypericin from Hypericum perforatum and serum kinetics of hypericin in man. Planta Med 57(Suppl 2): A61–A62
Thiede H-M, Walper A . (1994): Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 7(Suppl 1): S54–S56
van Harten J . (1993): Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24: 203–220
Vitiello B . (1999): Hypericum perforatum extracts as potential antidepressants. J Pharm Pharmacol 51: 513–517
Volz H-P . (1997): Controlled clinical trials of hypericum extracts in depressed patients—an overview. Pharmacopsychiatry 30(Suppl 2): 72–76
Wheatley D . (1998): Hypericum extract. Potential in the treatment of depression. CNS Drugs 9: 431–440
Wong DT, Bymaster FP, Engleman EA . (1995): Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57: 411–441
Wonnemann M, Singer A, Müller WE . (2000): Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort. The role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188–197
Yu PH . (2000): Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain. Pharmacopsychiatry 33: 60–65
Acknowledgements
We thank Dr. Georg Jückel (Department of Psychiatry, Ludwig Maximilians University, Munich, Germany) for kindly supplying us with the hypericum extracts used in this study. We also thank Eli Lilly, Pfizer, and Wyeth Research for their generous gifts of fluoxetine, sertraline, and WAY-100635, respectively. This work was supported by Grant MH-23433 from the National Institute of Mental Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fornal, C., Metzler, C., Mirescu, C. et al. Effects of Standardized Extracts of St. John's Wort on the Single-Unit Activity of Serotonergic Dorsal Raphe Neurons in Awake Cats: Comparisons with Fluoxetine and Sertraline. Neuropsychopharmacol 25, 858–870 (2001). https://doi.org/10.1016/S0893-133X(01)00297-4
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00297-4
Keywords
This article is cited by
-
Role of serotonergic dorsal raphe neurons in hypercapnia-induced arousals
Nature Communications (2020)
-
New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?
CNS Drugs (2016)
-
Metabolite profiling and fingerprinting of Hypericum species: a comparison of MS and NMR metabolomics
Metabolomics (2014)
